Lumos Diagnostics (ASX:LDX) has surged +140% to sell at 7cps in Wednesday’s lunchtime trade after inking a $420 million deal ...

FebriDx® is a first-in-class rapid test that differentiates between bacterial and non-bacterial respiratory infections, offering significant potential to address critical unmet needs in patient care ...

Lumos Diagnostics shares today soared by more than 150pc after the company unveiled a US distribution deal worth as much as ...

British researchers who tested almost 1,000 patients with the allergy, found almost 90 per cent could actually safely use the drug.

EPHA4 pathway dysfunction causes axon pathfinding defects, resulting in impaired coordinated left-right locomotion by disrupting neural patterning and the function of central pattern generators, ...

BiomX has dosed the first subject in the randomised Phase IIb trial of the company’s fixed multi-phage therapy, BX004, to ...

New bacterial mRNA vaccine technology shows promise in fighting plague, and could help address the global threat of ...

A study conducted by Martin SAMPHIRE and colleagues at Bangor University in the UK addresses this question through a ...

Progress towards The Lancet Commission on Global Surgery's 2030 targets has been too slow and too patchy, particularly in low ...

Removing incorrect penicillin allergy labels could improve care, reduce NHS costs and help tackle bacterial resistance, ...

Removing incorrect labels could help improve care for patients while tackling antibiotic resistance and saving money for the ...

Matthias Rillig’s research reveals a range of impacts of microplastics on soil-dwelling worms, bacteria, and plants—some of ...